Is Cardioprotection Dead?

Area of Science:

• Cardiology
• Regenerative Medicine
• Cell Therapy

Background:

• Acute myocardial infarction (AMI) treatment has long sought to mitigate lethal cardiac injury.
• Early reperfusion is the only proven therapy, despite decades of research into cardioprotection.
• The limited success of cardioprotective strategies raises questions about their viability.

Purpose of the Study:

• To explore cellular postconditioning as a novel therapeutic principle for AMI.
• To investigate the cardioprotective effects of cardiosphere-derived cells (CDCs) administered after reperfusion.
• To assess the long-term structural and functional benefits of CDC therapy in cardiac injury.

Main Methods:

• Administration of cardiosphere-derived cells (CDCs) in a postconditioning strategy.
• Evaluation of infarct size reduction in the acute phase post-reperfusion.
• Assessment of long-term structural and functional cardiac outcomes.

Main Results:

• Postconditioning with CDCs significantly limited infarct size acutely.
• CDC administration provided sustained structural and functional improvements over the long term.
• Evidence suggests CDCs possess cardioprotective rather than solely regenerative properties.

Conclusions:

• Cellular postconditioning with CDCs represents a promising therapeutic approach for acute myocardial infarction.
• This strategy offers both acute infarct size reduction and long-term cardiac benefits.
• Further research into cell therapy as a cardioprotective agent is warranted before abandoning the pursuit.